Health Care

Novartis AG remains a Swiss pharma powerhouse amid market volatility, showcasing strong growth, a robust pipeline, and resilient investor confidence.

Revolution Medicines’ May 28, 2026 SEC filing shows a major 10b5‑1 trade: Anthony Mancini bought and sold shares, exercised 3,121 options, boosting his holding to ~106 k shares—stock closed at $157.48 and the company’s market cap is $32.53 bn.

Pfizer’s new oncology wins: 7‑year CROWN data shows LORBRENA beats standard care, TALAPRO‑3 reduces prostate cancer progression, and a $10.5 b partnership with Innovent boosts China reach and future earnings.

Amgen’s latest investor outreach, market positioning and collaborative drug trials highlight its biotech leadership and AI‑driven innovation potential.

FDA approves Afrezza inhaled insulin for kids – MannKind’s breakthrough offers teens a quick, injection‑free diabetes option, boosting control and adherence.

Hyperliquid (HYPE) surges past $67 amid CFTC approval, institutional ETF plans, and buy‑back momentum, positioning it for a $75‑$100 rally and growing DeFi dominance.

Discover how AstraZeneca’s recent FDA approval of Imfinzi for bladder cancer and targeted anselamimab results reshape its oncology strategy and market outlook.

Hydreight Technologies Inc., a Vancouver‑based TSX Venture Exchange capital‑pool company, is strategically investing in high‑potential health‑care businesses, driving growth and innovation in the sector with a market cap of CAD 225 M.

Mirum Pharmaceuticals drives innovation in cholestatic liver disease therapy, boasting a $5.94B market cap and Nasdaq presence while investing heavily in R&D to improve patient outcomes.

Formycon AG’s Q1 2026 results tripled revenue to €13.1 m, powered by FYB203 sales, while tightening EBITDA loss and boosting the biosimilar pipeline for future growth.